eligibility_summary
Eligible: adults ≥18 with RRMM, ≥2 prior lines incl PI, IMiD, CD38 Ab, ECOG 0–1, measurable disease or ≥2 cm plasmacytoma. HIV OK if suppressed. Need adequate organs, >35 kg, contraception, proximity/monitoring for step‑up dosing. Exclude: aggressive/CNS disease, PCL/WM/POEMS/AL, other active cancers, significant infection/autoimmunity, major heart/renal/lung disease, recent transfusion/live vaccines/investigational/MM therapy, SCT washouts. Teclistamab: no prior gene‑mod ACT, Talquetamab: CAR‑T/BCMA OK, no GPRC5D or ≥Gr3 CRS.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, two-arm outpatient study in RRMM testing: 1) Teclistamab (TECVAYLI) – a humanized IgG4 bispecific T‑cell–engager monoclonal antibody that binds CD3 on T cells and BCMA on malignant B‑lineage/plasma cells to trigger T‑cell cytotoxicity. 2) Talquetamab (TALVEY) – a humanized IgG4 bispecific T‑cell–engager that binds CD3 on T cells and GPRC5D on myeloma cells to induce T‑cell killing. Prophylactic tocilizumab (Actemra) – an anti–IL‑6 receptor monoclonal antibody – is used to mitigate cytokine release syndrome. Targets/pathways: CD3 T‑cell activation, BCMA+ plasma cells, GPRC5D+ myeloma cells, and IL‑6/IL‑6R signaling (CRS).